Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nectin-4 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily and the nectin family of cell adhesion molecules. It mediates Ca²⁺–independent cell-cell adhesion and plays a key role in forming adherens junctions (AJs) and tight junctions (TJs). Nectin-4 is involved in various biological processes, including cell-cell aggregation, migration, proliferation of tumor cells, and EMT. It is overexpressed in multiple cancers and mutations cause ectodermal dysplasia-syndactyly syndrome type 1.
Nectin-4 is targeted in cancer therapy, particularly urothelial carcinoma, with the goal of disrupting cell-cell adhesion, proliferation, and survival signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nectin cell adhesion molecule – Nectin‐ ⁴ (NECTIN4).